The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines

Linn Reinholdt(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Maria Bach Laursen(Chr. Hansen (Denmark)), Hans Erik Johnsen(Herlev Hospital), Julie Støve Bødker(Chr. Hansen (Denmark)), Martin Bøgsted(Chr. Hansen (Denmark)), Lasse Hjort Jakobsen(Aalborg University Hospital)

Biomarker Research

June 14, 2016

10.1186/s40364-016-0067-2

Cited by 31

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

|Leukemia|2015|256